Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics

Status Recruiting

Clinical Trial Summary

Suicide is a leading cause of death for children and adolescents. Since warning signs of suicide and links to precipitating events differ between age groups, suicide can be difficult to predict. As a result, children often seek care for suicidal ideation (SI) in the emergency department (ED) where a limited number of treatment options exist. Current psychotherapies and pharmacotherapies, such as antidepressants, provide benefit over weeks or months and thus limits their effective application in the ED. Consequently, when there is an imminent threat to the child's safety, the typical management solution is to admit the patient to a safe environment and hopefully de-escalate over time. To address a more rapid-onset treatment option for SI, a number of studies in adults have suggested that a single, sub-anesthetic dose of intravenous ketamine can rapidly reduce depression and SI severity. These results are promising, but large-scale trials are needed to determine if ketamine is a safe and effective treatment for acute suicidality in the pediatric population. This approach has the benefit of working rapidly, avoiding involuntary hospitalizations, and protecting patients from self-harm until they can be connected to longer term mental health resources. This study will compare the use of intravenous ketamine to both active and placebo controls in children 10 to 17 years of age presenting to the pediatric ED for SI. The primary objective of this pilot trial is to explore the adequacy and range of three instruments measuring suicidality and to determine the sample size required for a large definitive randomized control trial. This larger trial will be used to estimate the effectiveness of intravenous ketamine for reducing SI in children in the pediatric ED. The secondary objectives are to assess study feasibility and optimize study procedures. Given very few side effects reported in adult studies and the relatively benign nature of those reported, the investigators do not expect any major safety concerns in the study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Suicidal Ideation

Clinical Trial Details

NCT number	NCT04955470
Study type	Interventional
Source	University of British Columbia
Contact	Karly Stillwell
Phone	(604) 875-2345
Email	kstillwell@bcchr.ca
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	June 1, 2022
Completion date	December 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05334381` - Navigating Mental Health Treatment for Black Youth	N/A
Recruiting	`NCT04653337` - Neuroimaging Guided and Robot-assisted rTMS for Suicidal Ideation of Depression	Phase 2
Terminated	`NCT04254809` - Evaluation of a Computerized Intervention for Learning to Re-Evaluate Suicidal Thoughts	N/A
Recruiting	`NCT05848089` - Real-time Intervention for Suicide Risk Reduction	N/A
Recruiting	`NCT06322199` - Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy Attempted Suicide Short Intervention Program (ASSIP) on Neuropsychological Correlates and Psychological Process Factors - Project 3
Completed	`NCT05280756` - Home-based tDCS for Prevention of Suicidal Ideation	N/A
Not yet recruiting	`NCT06454136` - Pilot Trial of Mobile Technology for Adolescent Suicidality	N/A
Completed	`NCT01944293` - Ketamine for Suicidality in Bipolar Depression	Phase 1/Phase 2
Completed	`NCT02021344` - Mental Health First Aid for College Students	N/A
Not yet recruiting	`NCT04686162` - Bae: A Smartphone Application for a Better Following Adolescents at Risk of Suicidal Behavior: Study of Acceptability and Preliminary Results of Efficacy	N/A
Recruiting	`NCT05377177` - Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI	N/A
Completed	`NCT05580757` - Pharmacists as Gate Keepers in Suicide Prevention: Needs of Pharmacists
Recruiting	`NCT05925322` - Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality	N/A
Not yet recruiting	`NCT05427734` - Treating Drivers of Suicide Using Jaspr Health	N/A
Recruiting	`NCT04112368` - Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach	Phase 4
Completed	`NCT04026308` - Written vs Electronic Safety Planning Study	N/A
Recruiting	`NCT05537376` - A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness	N/A
Not yet recruiting	`NCT06311591` - Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part B	N/A
Recruiting	`NCT05894980` - How to Reduce Suicidal Thoughts and Impulsivity in Depression	N/A
Not yet recruiting	`NCT05860257` - Transforming Adolescent Mental Health Through Accessible, Scalable, Technology-supported Small-group Instruction	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics — Keta4SI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms